Fabry Disease
Conditions
Keywords
Fabry disease, Fabry cardiomyopathy, cardiac MRI, CMR, T1 mapping, T2mapping
Brief summary
This study will evaluate whether cardiac MRI T1 and T2 mapping improves our ability to detect early abnormalities in the heart in patients with Fabry disease and identify patients at increase risk of adverse events.
Detailed description
Fabry disease is an inherited disorder that affects many organs in the body, including the heart. Men and women are both affected, with average life expectancy reduced by 10-20 years. The heart muscle can become thick and scarred in over half of patients, eventually resulting in heart failure, abnormal rhythm and death. The focus of this study will be on improving the detection of early heart disease before irreversible damage has occurred in order to improve patient outcomes. It is hypothesized that new cardiac MRI techniques called T1 and T2 mapping will improve the ability to detect early abnormalities in the heart. Early detection of cardiac disease may enable a personalized treatment approach, potentially improving patient outcomes. The results of the study will identify which patients might benefit from early initiation of treatment to prevent bad outcomes in the future by using cardiac MRI to identify those at higher risk.
Interventions
DIAGNOSTIC_TESTCardiac MRI, ECG/Holter and Blood Biomarkers
Cardiac MRI including T1/T2 mapping, ECG and blood biomarker evaluation will be performed at baseline and follow-up
Sponsors
University Health Network, Toronto
Vancouver General Hospital
The Cleveland Clinic
Icahn School of Medicine at Mount Sinai
IRCCS Policlinico S. Donato
Alberta Health services
Libin Cardiovascular Institute of Alberta
Vancouver Coastal Health
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
cardiac MRI
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Fabry disease; * Age ≥ 18 years.
Exclusion criteria
* History of myocardial infarction; * Contraindication to MRI.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major Adverse Cardiac Events (MACE) | 5 years | MACE will be assessed as a composite endpoint defined by the development on one or more of events such as sustained ventricular tachycardia (VT), severe bradycardia, heart failure hospitalization and cardiac death. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The FAbry STabilization indEX (FASTEX) score | 3 years | FAbry STabilization indEX (FASTEX) score will be evaluated to assess clinical stability or progression of Fabry disease at follow-up. FASTEX score change of ≥20% will be considered an indication of clinical worsening at follow-up. Minimum value 0%. No maximum value. Higher score change indicates worse outcome. |
Countries
Canada
Contacts
CONTACTKate Hanneman
PRINCIPAL_INVESTIGATORKate Hanneman
University Health Network, Toronto
Outcome results
None listed